CDK5 and glioblastoma: This biosensor does not respond to ATP or the ATP-competitive inhibitor Roscovitine and was therefore implemented to screen for small molecules that would target CDK5 without binding the ATP pocket and potentially inhibit its activity and glioblastoma cell proliferation, resulting in the discovery of a class of quinazolinone derivatives.